170 related articles for article (PubMed ID: 29481492)
1. Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.
Gonzalez-Cao M; Mayo de Las Casas C; Jordana Ariza N; Manzano JL; Molina-Vila MÁ; Soriano V; Puertolas T; Balada A; Soria A; Majem M; Montagut C; Muñoz E; Rodriguez-Abreu D; Perez E; Garcia A; Cortes J; Drozdowskyj A; Karachaliou N; Rosell R;
Melanoma Res; 2018 Jun; 28(3):195-203. PubMed ID: 29481492
[TBL] [Abstract][Full Text] [Related]
2. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.
Momtaz P; Pentsova E; Abdel-Wahab O; Diamond E; Hyman D; Merghoub T; You D; Gasmi B; Viale A; Chapman PB
Oncotarget; 2016 Dec; 7(51):85430-85436. PubMed ID: 27863426
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
Gonzalez-Cao M; Mayo-de-Las-Casas C; Molina-Vila MA; De Mattos-Arruda L; Muñoz-Couselo E; Manzano JL; Cortes J; Berros JP; Drozdowskyj A; Sanmamed M; Gonzalez A; Alvarez C; Viteri S; Karachaliou N; Martin Algarra S; Bertran-Alamillo J; Jordana-Ariza N; Rosell R
Melanoma Res; 2015 Dec; 25(6):486-95. PubMed ID: 26366702
[TBL] [Abstract][Full Text] [Related]
4. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
5. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.
Board RE; Ellison G; Orr MC; Kemsley KR; McWalter G; Blockley LY; Dearden SP; Morris C; Ranson M; Cantarini MV; Dive C; Hughes A
Br J Cancer; 2009 Nov; 101(10):1724-30. PubMed ID: 19861964
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
7. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.
Janku F; Huang HJ; Claes B; Falchook GS; Fu S; Hong D; Ramzanali NM; Nitti G; Cabrilo G; Tsimberidou AM; Naing A; Piha-Paul SA; Wheler JJ; Karp DD; Holley VR; Zinner RG; Subbiah V; Luthra R; Kopetz S; Overman MJ; Kee BK; Patel S; Devogelaere B; Sablon E; Maertens G; Mills GB; Kurzrock R; Meric-Bernstam F
Mol Cancer Ther; 2016 Jun; 15(6):1397-404. PubMed ID: 27207774
[TBL] [Abstract][Full Text] [Related]
8. Diversity of circulating tumor cells in peripheral blood: Detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis.
Kiniwa Y; Nakamura K; Mikoshiba A; Akiyama Y; Morimoto A; Okuyama R
J Dermatol Sci; 2018 May; 90(2):211-213. PubMed ID: 29426605
[No Abstract] [Full Text] [Related]
9. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
10. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES
Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992
[TBL] [Abstract][Full Text] [Related]
11. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
14. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
Santiago-Walker A; Gagnon R; Mazumdar J; Casey M; Long GV; Schadendorf D; Flaherty K; Kefford R; Hauschild A; Hwu P; Haney P; O'Hagan A; Carver J; Goodman V; Legos J; Martin AM
Clin Cancer Res; 2016 Feb; 22(3):567-74. PubMed ID: 26446943
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients.
Kaneko A; Kanemaru H; Kajihara I; Mijiddorj T; Miyauchi H; Kuriyama H; Kimura T; Sawamura S; Makino K; Miyashita A; Aoi J; Makino T; Masuguchi S; Fukushima S; Ihn H
J Dermatol Sci; 2021 Jun; 102(3):158-166. PubMed ID: 34049769
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
[TBL] [Abstract][Full Text] [Related]
18. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
19. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
20. Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma.
Sener E; Yildirim P; Tan A; Gokoz O; Tezel GG
Pathol Res Pract; 2017 May; 213(5):522-530. PubMed ID: 28216139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
